业界动态监管公开信息 · FDA

FDA批准度伐利尤单抗联合恩诺单抗维多汀-ejfv用于肌层浸润性膀胱癌

FDA Drugs · 2026-11-14 02:22

正文 · 中文译文

FDA批准度伐利尤单抗联合enfortumab vedotin-ejfv用于肌层浸润性膀胱癌 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已证实临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2026年11月13日,美国食品药品监督管理局(FDA)批准度伐利尤单抗(Imfinzi,阿斯利康)联合enfortumab vedotin-ejfv作为新辅助治疗,随后在根治性膀胱切除术后以度伐利尤单抗单药作为辅助治疗,用于治疗不适合接受或拒绝接受顺铂为基础化疗的肌层浸润性膀胱癌(MIBC)成人患者。 Imfinzi的完整处方信息将发布在Drugs@FDA上。 疗效与安全性 疗效在VOLGA(NCT04960709)这项随机、开放标签试验中进行了评估。该试验按1:1:1随机分配695例适合接受根治性膀胱切除术(RC)且不适合接受或拒绝接受顺铂为基础化疗的MIBC患者,分别接受术前新辅助度伐利尤单抗联合enfortumab vedotin-ejfv治疗后序贯辅助度伐利尤单抗、单纯RC,或另一种研究性联合方案。 主要疗效结局指标为盲法独立中心审查评估的无事件生存期(EFS)。总生存期(OS)为另一项疗效结局指标。 该试验表明,与单纯RC相比,度伐利尤单抗/恩诺单抗维多汀-ejfv在EFS和OS方面均显示出统计学显著改善。度伐利尤单抗/恩诺单抗维多汀-ejfv组的中位EFS未达到(NR)(95% CI:33.2,NR),单纯RC组为12.1个月(95% CI:7.6,27.0)(风险比0.51 [95% CI:0.38,0.67];双侧p值< 0.0001)。度伐利尤单抗/恩诺单抗维多汀-ejfv组和单纯RC组的中位OS均未达到(风险比0.58 [95% CI:0.40,0.83];双侧p值0.0027)。 度伐利尤单抗处方信息包括对免疫介导的不良反应、输注相关反应、异基因造血干细胞移植并发症及胚胎-胎儿毒性的警告和注意事项。 度伐利尤单抗联合恩诺单抗维多汀-ejfv最常见的不良反应(> 20%),包括实验室异常,为AST升高、ALT升高、血红蛋白降低、皮疹、肌酐升高、瘙痒、钙降低、脂肪酶升高、钾升高、尿路感染、淀粉酶升高、疲乏、钠降低、淋巴细胞降低、腹泻、白细胞降低、便秘、食欲降低、碱性磷酸酶升高、味觉障碍、恶心、周围神经病、肌肉骨骼疼痛和脱发。 推荐剂量 对于体重≥30 kg的患者,推荐的度伐利尤单抗剂量为1,500 mg每3周一次,联合新辅助恩沃利单抗维多汀-ejfv 1.25 mg/kg(每周期第1天和第8天)术前治疗3个周期,术后继以度伐利尤单抗1,500 mg单药每4周一次,最多9个周期。对于体重<30 kg的患者,推荐的度伐利尤单抗剂量为20 mg/kg每3周一次,联合新辅助恩沃利单抗维多汀-ejfv 1.25 mg/kg(每周期第1天和第8天)术前治疗3个周期,术后继以度伐利尤单抗20 mg/kg单药每4周一次,最多9个周期。治疗应持续至疾病进展以致无法进行根治性手术、复发或出现不可接受的毒性,或术后最多9个周期。 本审评在Project Orbis框架下开展,该项目为美国食品药品监督管理局(FDA)肿瘤卓越中心的一项倡议。Project Orbis为国际合作伙伴之间肿瘤药物的同步提交和审评提供了框架。本次审评中,FDA与澳大利亚治疗用品管理局(TGA)、巴西卫生监管局(ANVISA)、加拿大卫生部、以色列卫生部(IMoH)、新加坡卫生科学局(HSA)以及英国药品和保健产品监管局(MHRA)合作。相关申请可能正在其他监管机构进行提交程序或仍处于审评中。 本综述使用了评估辅助工具(Assessment Aid),这是申请人自愿提交的材料,用以协助FDA的评估。FDA比FDA目标日期提前六周批准了该申请。 该申请获得了优先审评。FDA加速审批项目的说明见《行业指南:严重疾病药物和生物制品的加速审批项目》。 医疗专业人员应将所有怀疑与使用任何药物和器械相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 如需获取研究性肿瘤产品单患者IND方面的协助,医疗专业人员可联系OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov 内容截至日期: 2026年11月13日 受监管产品 药物 肿瘤学

正文 · 英文原文

FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On November 13, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment after radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for or who have refused cisplatin based chemotherapy. Full prescribing information for Imfinzi will be posted on Drugs@FDA. Efficacy and Safety Efficacy was evaluated in VOLGA (NCT04960709), a randomized, open-label trial. The trial randomized (1:1:1) 695 patients with MIBC who were candidates for radical cystectomy (RC) and who were ineligible for or who refused cisplatin-based chemotherapy to receive neoadjuvant durvalumab and enfortumab vedotin-ejfv prior to surgery followed by adjuvant durvalumab, RC alone, or an additional investigational combination regimen. The major efficacy outcome measure was event-free survival (EFS) by blinded independent central review assessment. Overall survival (OS) was an additional efficacy outcome measure. The trial demonstrated statistically significant improvements in both EFS and OS for durvalumab/enfortumab vedotin-ejfv compared to RC alone. Median EFS was not reached (NR) (95% CI: 33.2, NR) in the durvalumab/enfortumab vedotin-ejfv arm and was 12.1 months (95% CI: 7.6, 27.0) in the RC alone arm (hazard ratio 0.51 [95% CI: 0.38, 0.67]; two-sided p-value < 0.0001). Median OS was not reached in either the durvalumab/enfortumab vedotin-ejfv arm or the RC alone arm (hazard ratio 0.58 [95% CI: 0.40, 0.83]; two-sided p-value 0.0027). The durvalumab prescribing information includes warnings and precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicities. The most common adverse reactions (> 20%), including laboratory abnormalities, for durvalumab in combination with enfortumab vedotin-ejfv were increased AST, increased ALT, decreased hemoglobin, rash, increased creatinine, pruritus, decreased calcium, increased lipase, increased potassium, urinary tract infection, increased amylase, fatigue, decreased sodium, decreased lymphocytes, diarrhea, decreased leukocytes, constipation, decreased appetite, increased alkaline phosphatase, dysgeusia, nausea, peripheral neuropathy, musculoskeletal pain, and alopecia. Recommended Dosage The recommended durvalumab dose for patients with a body weight of ≥30 kg is 1,500 mg every 3 weeks in combination with neoadjuvant enfortumab vedotin-ejfv 1.25 mg/kg (on Days 1 and 8 of each cycle) for 3 cycles prior to surgery, followed by durvalumab 1,500 mg as a single agent every 4 weeks for up to 9 cycles after surgery. The recommended durvalumab dose for patients with a body weight <30 kg is 20 mg/kg every 3 weeks in combination with neoadjuvant enfortumab vedotin-ejfv 1.25 mg/kg (on Days 1 and 8 of each cycle) for 3 cycles prior to surgery, followed by durvalumab 20 mg/kg every 4 weeks as a single agent for up to 9 cycles after surgery. Treatment should continue until disease progression that precludes definitive surgery, recurrence, or unacceptable toxicity, or a maximum of 9 cycles after surgery. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, Israel’s Ministry of Health (IMoH), Singapore’s Health Sciences Authority (HSA), and the United Kingdon’s Medicines and Healthcare products Regulatory Agency (MHRA). The applications may be undergoing the submission process or still be under review at the other regulatory agencies. This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application six weeks ahead of the FDA goal date. This application was granted priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov Content current as of: 11/13/2026 Regulated Product(s) Drugs Oncology

English
FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界